Aortic stenosis has long been viewed as a mechanical problem: calcium accumulates on the aortic valve over decades, the valve opening narrows, and the heart struggles to push blood through. But the new study reinforces a very different picture that has been emerging over the past two decades. Degenerative aortic stenosis is an actively inflammatory process, sharing many of the same cellular and molecular players that drive atherosclerosis, including oxidized lipids, monocytes, T lymphocytes, and pro-inflammatory signaling cascades. The authors frame this within the concept of inflammaging, the chronic, low-grade, sterile inflammation that rises with age and feeds a vicious cycle accelerating structural cardiovascular changes, cardiometabolic disease, and valvular calcification simultaneously.

The RCII is designed to quantify precisely that intersection. It is calculated as the product of remnant cholesterol, the cholesterol carried in triglyceride-rich lipoprotein particles, and high-sensitivity C-reactive protein, divided by ten. Remnant cholesterol is obtained by subtracting HDL and LDL cholesterol from total cholesterol, making it derivable from any standard lipid panel. Remnant particles are considered highly atherogenic because they infiltrate the arterial intima, activate vascular and immune cells, and promote endothelial dysfunction and cholesterol deposition. C-reactive protein, meanwhile, is a hallmark of inflammaging, activating the complement system, recruiting macrophages to arterial walls, and promoting cytokine production and plaque vulnerability. Multiplying the two creates an index that reflects the joint burden of lipid-driven and inflammation-driven vascular injury.

The study population consisted of elderly patients, averaging 83.5 years of age and predominantly female, referred to the outpatient clinic of the Ospedale del Cuore in Massa, Italy, between March 2016 and March 2020. All had severe aortic stenosis with preserved left ventricular systolic function and underwent a multidisciplinary heart team evaluation including clinical, surgical, laboratory, and multidimensional geriatric assessment. The cohort carried a heavy cardiometabolic burden: 88 percent had hypertension, 74 percent had dyslipidemia, and 36 percent had type 2 diabetes. Frailty was assessed using the Fried phenotype criteria, and every patient was classified as at least pre-frail. Patients with acute heart failure, hemodynamic shock, or active infection were excluded to avoid distorting the inflammatory biomarkers under study.

The correlation analysis produced a strikingly coherent pattern. RCII levels correlated most strongly with interleukin-6, a central pro-inflammatory cytokine, with a correlation coefficient of 0.6, and also showed significant positive associations with neutrophils, the neutrophil-to-lymphocyte ratio, monocytes, platelets, erythrocyte sedimentation rate, and fibrinogen. Positive correlations, albeit weaker, emerged with glucose and creatinine, pointing toward disturbed glucose metabolism and renal involvement. The index also correlated with vascular endothelial growth factor, a mediator of the angiogenesis that occurs within calcified valves, and with frailty scores, suggesting that RCII may capture a multisystem vulnerability rather than a single disease process. Inverse correlations appeared with albumin, which typically falls during inflammatory states, and with HDL cholesterol, indicating that a high RCII reflects an unfavorable metabolic profile.

The survival findings carried the study’s most consequential implication. Over a mean follow-up of 19 months, ten cardiovascular deaths occurred. Kaplan-Meier analysis showed significantly worse survival among patients whose RCII exceeded the 75th percentile, a threshold of 17.6. In an exploratory multivariable Cox regression, higher RCII remained associated with cardiovascular mortality with a hazard ratio of 3.5, alongside elevated neutrophil counts, which showed a hazard ratio of 5.1. The authors are careful to stress, however, that the confidence interval for the RCII estimate was wide, spanning from 1.0 to 12.0, and that the small number of deaths limits statistical power. They explicitly describe the association as exploratory and hypothesis-generating rather than evidence of an established independent prognostic role.

Beneath the statistical associations lies a plausible molecular mechanism centered on the NLRP3 inflammasome, a multiprotein complex that, when activated, triggers caspase-1 and drives the release of pro-inflammatory cytokines such as interleukin-6, prompting the liver to produce C-reactive protein and fibrinogen. Oxidized LDL particles are important regulators of this inflammasome, making it a candidate link between the cholesterol pathway and vascular inflammation. In the context of aortic stenosis, NLRP3 activation promotes the transformation of valvular interstitial cells into bone-like cells, driving osteogenic calcification, and experimental studies have shown that blocking the inflammasome can reduce or reverse valve calcification in animal models. The same pathway has been implicated in frailty, sarcopenia, and cognitive decline, which may explain why a biomarker combining lipid and inflammatory signals tracked so closely with frailty in this cohort.

This mechanistic overlap also opens a therapeutic horizon. Drugs that target the NLRP3 inflammasome or its downstream interleukin-1 signaling, including anakinra, colchicine, canakinumab, and rilonacept, could in principle counteract inflammaging, atherosclerosis, and valvular calcification simultaneously. The authors also note that RCII is actionable in a broader sense, since both of its components can be modified by lipid-lowering and anti-inflammatory strategies or lifestyle changes. Yet they caution that therapies effective in atherosclerosis have not consistently shown benefit in aortic stenosis, and no pharmacological treatment currently exists to prevent or delay the progression of calcific valve disease, which is why sensitive biomarkers capable of detecting early, still-modifiable disease stages are so urgently needed.

The study has important limitations that the authors confront directly. It was retrospective, IL-6 and VEGF were measured in only 23 of the 103 patients, and the low number of cardiovascular deaths raises the risk of model instability and overfitting in the multivariable analysis. The study also cannot establish whether RCII adds predictive information beyond established clinical variables such as age, frailty, diabetes, renal function, BNP, aortic valve gradient, prior myocardial infarction, and treatment strategy. Before any clinical adoption, the authors call for external validation, standardized thresholds, serial measurements, and head-to-head comparison with established risk prediction models.

Even with those caveats, the appeal of RCII is hard to ignore. It requires no new technology, no specialized assay, and no additional blood draw, being computable from a routine lipid panel and a standard C-reactive protein measurement. Prior studies have linked the index to stroke risk, all-cause and cardiovascular mortality, metabolic syndrome, diabetes incidence, and short-term mortality in acute decompensated heart failure, with some large population analyses finding nearly sevenfold higher odds of metabolic syndrome in the highest RCII quartile. If larger prospective studies confirm the Italian team’s preliminary signal, this low-cost index could help clinicians identify which elderly patients with aortic stenosis carry the greatest hidden inflammatory-metabolic risk, opening a window for earlier, personalized prevention in a population where every month of modifiable risk matters.

Subject of Research: The remnant cholesterol inflammatory index as a predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article Title: Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article References: Mazzone, A., Gaggini, M., Foffa, I., Del Turco, S., Minichilli, F., Berti, S., & Vassalle, C. (2026). Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis. Frontiers in Endocrinology, 17, Article 1894558. https://doi.org/10.3389/fendo.2026.1894558

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1894558

Keywords: aortic stenosis, remnant cholesterol inflammatory index, inflammaging, cardiovascular mortality, C-reactive protein, frailty, NLRP3 inflammasome, cardiometabolic risk, elderly patients, biomarker, interleukin-6, valve calcification

The research team, led by Tímea K. Turschl and Béla Merkely, enrolled 300 patients scheduled for TAVI at their institute between April 2020 and December 2023, with a mean age of 78.7 years. Each patient underwent detailed transthoracic echocardiography and blood pressure measurement 24 to 48 hours before the procedure. Over a median follow-up of 25 months, 62 patients died from any cause. The investigators then asked a deceptively simple question: could a novel echocardiographic index, computed from routine images and a blood pressure cuff, predict who would survive and who would not?

To understand the innovation, it helps to trace the evolution of cardiac function assessment. The gold standard for measuring the heart’s intrinsic contractility is the pressure–volume loop, obtained by threading a conductance catheter into the left ventricle during cardiac catheterization. This invasive technique plots ventricular pressure against volume throughout the cardiac cycle, yielding load-independent indices of myocardial performance. Because of its complexity and risk, it is reserved for a handful of selected patients and cannot be used routinely. Echocardiography, by contrast, is cheap, safe and ubiquitous, but its most popular outputs, ejection fraction and global longitudinal strain, are strongly load-dependent, meaning they reflect not only the muscle’s contractile power but also the hemodynamic conditions imposed on it.

Pressure–strain loop-derived myocardial work analysis was introduced to bridge this gap. The method estimates the left ventricular pressure curve non-invasively by scaling a normalized reference pressure curve to the patient’s measured brachial systolic pressure, adding the Doppler-derived transvalvular gradient in aortic stenosis patients. This pressure trace is then integrated with strain curves obtained from speckle-tracking echocardiography, producing pressure–strain loops from which indices such as global work index, global constructive work, global wasted work and global work efficiency are calculated. Constructive work represents myocardial shortening during systole and lengthening during diastole, while wasted work captures the energetically futile deformation that occurs when segments contract against uncoordinated loads. Previous studies have shown these indices correlate well with invasive measures of contractility and outperform conventional parameters in predicting outcomes across cardiovascular diseases.

But the Hungarian team identified a blind spot: standard myocardial work indices ignore ventricular geometry and preload entirely. In aortic stenosis, chronic pressure overload drives concentric remodeling, and many elderly patients also carry volume overload and altered chamber sizes that fundamentally change how strain and pressure translate into actual mechanical output. Building on their earlier translational work in rodent models of heart failure, where pressure–strain–volume loops correlated even more strongly with gold-standard contractility than conventional work metrics, the researchers multiplied the pressure–strain loops by instantaneous left ventricular volume, frame by frame, before integration. The resulting volume-adjusted indices, GWIVi and GCWVi, were normalized to body surface area, yielding values expressed in mmHg%L per square meter.

The first striking result emerged when the cohort was divided into the three classic hemodynamic phenotypes of severe aortic stenosis: normal-flow high-gradient, classical low-flow low-gradient, and paradoxical low-flow low-gradient. Conventional measures told a familiar but incomplete story. Global longitudinal strain and standard work index were significantly reduced only in the classical low-flow low-gradient group, while paradoxical low-flow patients, who typically present with small, stiff, seemingly hypercontractile ventricles, looked comparable to normal-flow patients. The volume-adjusted GWIVi, however, revealed that both low-flow subgroups shared a similarly depressed myocardial work capacity, at 46.98 and 51.99 mmHg%L/m² respectively, compared with 63.74 in the normal-flow high-gradient group, a difference that was highly significant. In other words, the new index unmasked ventricular dysfunction that standard echocardiographic parameters underestimated in the paradoxical phenotype.

The prognostic findings were equally compelling. In univariate analysis, ejection fraction failed to predict mortality at all, while global longitudinal strain, global constructive work, GWIVi and GCWVi were all significantly associated with survival. When the researchers constructed fully adjusted multivariable Cox regression models incorporating clinically relevant factors such as age, male sex, hemoglobin, atrial fibrillation and diabetes mellitus, only the volume-adjusted indices remained significant independent predictors. GWIVi carried a hazard ratio of 0.955 per unit increase, and adding either index significantly improved the fit of the clinical reference model according to likelihood-ratio testing, whereas ejection fraction, strain and standard work indices did not. GCWVi also predicted mortality independently of low-flow low-gradient status, demonstrating that its prognostic power was not simply a proxy for the hemodynamic subtype.

Perhaps most clinically relevant was the performance of the new index in patients with preserved ejection fraction, a notoriously difficult group in whom conventional markers often appear reassuring despite adverse outcomes. Among the 157 patients with an ejection fraction of 50 percent or higher, 32 died during follow-up. In this subgroup, only GCWVi and atrial fibrillation emerged as predictors of mortality, and GCWVi remained an independent predictor even after adjustment for age and sex. Kaplan–Meier analysis showed that patients with GCWVi values above the cohort median had significantly better survival, both in the total population and in the preserved ejection fraction subgroup, with log-rank p-values of 0.017 and 0.007 respectively. A representative case pair illustrated the point vividly: one patient with preserved ejection fraction and strain but low volume-adjusted work died 17 months after TAVI, while another with moderately reduced conventional measures but high GWIVi survived the entire follow-up period.

The implications extend beyond prognostication. TAVI has become the most common valvular procedure worldwide, yet no dedicated perioperative risk stratification system has gained general acceptance, and the widely used EuroSCORE II was designed for open-heart surgery. The authors argue that in hemodynamic overload states such as aortic stenosis, pressure–strain–volume analysis may provide a more physiologically accurate depiction of left ventricular function, precisely because it accounts for the chamber’s size and filling state rather than deformation alone. Encouragingly, the technique requires only minimal additional post-processing on top of routine echocardiography, using images and blood pressure data already collected before the procedure.

Important caveats remain. The study was single-center, all procedures used one ultrasound vendor, and the technique depends on adequate image quality for speckle-tracking and endocardial border contouring, which may have introduced selection bias toward patients with better echocardiographic windows. The authors themselves call for multicenter validation and methodological standardization before broader clinical implementation, and note that atrial and right ventricular strain, which are relevant prognostic markers in TAVI candidates, were not assessed. Still, the message is clear: by folding ventricular volume into the calculation of myocardial work, cardiologists may gain a window into the aging heart’s true contractile reserve, one that ejection fraction has never provided. For the growing population of elderly patients facing valve replacement, that window could mean better-informed decisions about when, and whether, to intervene.

Subject of Research: Non-invasive pressure-strain-volume loop analysis for predicting survival after transcatheter aortic valve implantation in aortic stenosis

Article Title: Integrating volumes into myocardial work: the prognostic role of non-invasive pressure-strain-volume analysis in transcatheter aortic valve implantation

Article References: Turschl, T. K., Ladányi, Z., Ferencz, A., Fábián, A., Tokodi, M., Szijártó, Á., Ruppert, M., Nagy, A., Molnár, A. Á., Molnár, L., Zima, E., Kovács, A., Lakatos, B. K., & Merkely, B. (2026). Integrating volumes into myocardial work: the prognostic role of non-invasive pressure-strain-volume analysis in transcatheter aortic valve implantation. GeroScience. https://doi.org/10.1007/s11357-026-02583-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02583-3

Keywords: aortic stenosis, TAVI, echocardiography, myocardial work, pressure-strain-volume loops, left ventricular function, ejection fraction, global longitudinal strain, prognosis, valvular heart disease, cardiac contractility, GeroScience

The technique at the center of the study, CT-derived fractional flow reserve or CT-FFR, deserves a moment of explanation because it is doing the heavy scientific lifting here. Fractional flow reserve is classically measured with a pressure wire threaded into a coronary artery during invasive catheterization; it expresses the ratio of blood pressure distal to a stenosis to the pressure available in the aorta, with values below 0.80 generally signaling ischemia that warrants stenting. CT-FFR replicates this measurement computationally. Software ingests the geometry of the coronary tree extracted from a coronary CT angiogram, models the physics of blood flow through it, and estimates the pressure drop across each lesion without ever entering the patient’s body. That means researchers can, in principle, measure the functional significance of coronary narrowings repeatedly over time, at low risk and low cost, which is exactly what made the present longitudinal design feasible.

The investigators took a retrospective look at patients who had undergone TAVR for aortic stenosis and who also happened to have coronary CT angiography both before the procedure and at least six months afterward. That second scan is not routine practice; it was obtained on the basis of individualized clinical decisions, which introduces some selection considerations the authors acknowledge. From the available records, 62 patients made it into the final analysis, contributing 112 coronary arteries for paired evaluation. Every included patient had at least one coronary stenosis of moderate severity, in the 30 to 90 percent range, at baseline. The median interval between the pre-procedure scan and the follow-up scan was 363 days, so the team was effectively comparing the coronary circulation one year apart, straddling the valve replacement.

The headline finding is counterintuitive: after the aortic valve was fixed, CT-FFR values across the studied arteries went down, not up. Across all vessels, the mean CT-FFR fell from 0.84 before TAVR to 0.82 afterward, a small but highly statistically significant decline. When the arteries were analyzed by vessel, the pattern became more textured. The right coronary artery dropped from 0.89 to 0.83, and the left circumflex artery fell from 0.82 to 0.79, both statistically significant changes. The left anterior descending artery, the largest and most clinically scrutinized coronary vessel, showed no significant change, edging from 0.84 to 0.85. None of these post-TAVR values crossed the conventional 0.80 ischemic threshold on average, but the direction of travel was consistent enough to demand an explanation.

The obvious first suspect was plaque progression. If atherosclerosis had advanced during the follow-up year, the pressure drop across lesions would increase and FFR would fall. So the researchers systematically compared qualitative plaque features, such as the presence of low-attenuation cores, spotty calcium and the napkin-ring sign, along with quantitative metrics like plaque volume and stenosis percentage, between the baseline and follow-up scans. The result was a null finding of real scientific value: no significant differences emerged in any qualitative or quantitative plaque characteristic. The atherosclerotic burden, as seen by CT, was essentially frozen in place. And when the team formally tested the relationship, they found no correlation between changes in CT-FFR and changes in plaque measurements, effectively ruling out plaque dynamics as the driver of the hemodynamic shift.

That leaves hemodynamics itself, and here the study offers a compelling clue. The left ventricular mass index, a measure of the thickness and bulk of the heart’s main pumping chamber, decreased significantly after TAVR, confirming the well-documented phenomenon of reverse remodeling: once the pressure overload of aortic stenosis is relieved, the hypertrophied muscle begins to shrink back toward normal. Intriguingly, the magnitude of LV mass regression showed a trend toward correlation with the change in CT-FFR, with a correlation coefficient of -0.183 and a P value of 0.054, just shy of conventional significance. The authors interpret this as evidence that the falling FFR values primarily reflect improved hemodynamics secondary to relief of the valve obstruction and ventricular remodeling, rather than any worsening of the coronary lesions themselves.

The physiology behind that interpretation is worth unpacking. Fractional flow reserve is not a fixed property of a stenosis; it depends on the flow of blood racing through the narrowed segment during maximal hyperemia. When the aortic valve is replaced, downstream resistance falls, the ventricle generates pressure more efficiently, and coronary flow patterns change in complex ways. Microvascular function, which is often abnormal in aortic stenosis, also evolves during recovery. Any of these shifts can alter the pressure gradient across a coronary lesion independent of its anatomy. In other words, the same anatomical narrowing can be functionally different in a remodeled heart, and the study’s data suggest that is precisely what CT-FFR is capturing in these patients.

For clinicians, the implications cut in two directions. On one hand, the findings are reassuring: a modest post-TAVR decline in CT-FFR, in a stable patient, does not appear to signal aggressive plaque growth and may simply be a byproduct of a heart recalibrating to its new pressure environment. On the other hand, the results are a caution against interpreting serial CT-FFR values in TAVR patients the way one would in ordinary stable chest pain populations. The reference frame changes after valve replacement, and a drop of a few hundredths in FFR may carry a very different meaning in a ventricle that is actively unloading and remodeling. The authors are careful to note that their conclusions apply primarily to clinically stable patients, and that follow-up CT angiography in this cohort was performed on individualized clinical grounds rather than as a standardized protocol.

The study also carries honest limitations that shape how far its message travels. It was retrospective and observational, with a modest sample of 62 patients, and the decision to obtain post-TAVR CCTA was not uniform, raising the possibility of selection effects. The follow-up window, while a median of nearly a year, captures only one snapshot of what is likely a longer remodeling trajectory. Still, the core contribution stands: this is one of the clearest demonstrations that after TAVR, coronary functional measurements and coronary anatomy can decouple, with FFR drifting downward while plaque burden holds steady. As CT-FFR becomes more widely adopted and as TAVR expands to younger and lower-risk patients, understanding this post-procedural hemodynamic evolution will matter for deciding which lesions truly need stenting and which are simply adapting to a heart that has been set free. The Shenyang team’s data suggest that, at least in the first year after valve replacement, the arteries themselves are not the story; the recovering ventricle is.

Subject of Research: Changes in CT-derived coronary fractional flow reserve and plaque characteristics after transcatheter aortic valve replacement

Article Title: Coronary hemodynamic and plaque changes following transcatheter aortic valve replacement

Article References: Fang, Y., An, C., Sun, Y., Wang, B., Wang, G., Liang, Z., Li, Y., Xu, K., & Han, Y. (2026). Coronary hemodynamic and plaque changes following transcatheter aortic valve replacement. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02763-9

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02763-9

Keywords: TAVR, aortic stenosis, CT-FFR, coronary CT angiography, fractional flow reserve, coronary plaque, left ventricular mass, reverse remodeling, cardiology, medical imaging, hemodynamics, BMC Medical Imaging

Calcific aortic valve disease exists on a continuum. It begins with aortic valve sclerosis, in which the valve leaflets thicken and develop focal areas of increased echogenicity on ultrasound, yet blood flow remains unobstructed and echocardiographic parameters stay within normal limits. Over years, this subclinical state can progress to aortic stenosis, the advanced hemodynamically significant phase in which the valve area shrinks, transvalvular pressure gradients climb, and the heart must strain to push blood through a narrowed orifice. The epidemiology is sobering. The prevalence of aortic stenosis rises from roughly 0.2 percent among people aged 50 to 59 to nearly 10 percent among those aged 80 to 89, while aortic valve sclerosis affects an estimated 25 to 40 percent of individuals between 65 and 75. Because sclerosis is usually silent, most patients are identified only once significant stenosis has developed, at which point surgical or interventional valve replacement remains the sole effective therapy. Untreated severe symptomatic stenosis carries a high mortality, making the search for early molecular markers and therapeutic targets a clinical priority.

The conceptual framework behind the new work draws heavily on atherosclerosis. Calcific aortic valve disease shares key clinical, structural, and molecular features with the arterial disease, suggesting overlapping pathogenetic mechanisms. In both conditions, disease initiation is marked by lipid accumulation within the subendothelial layer, whether in the arterial wall or in the valve leaflets themselves. Lipid deposition promotes local inflammation, macrophage activation, and foam cell formation, ultimately contributing to calcification. In both settings, progressive mineralization increases tissue stiffness, reducing compliance and, in the valve, generating hemodynamic obstruction. Inflammation is a central driver of this process. Endothelial dysfunction triggered by hypertension, diabetes, hyperlipidemia, and smoking recruits immune cells including macrophages and T cells, which release proinflammatory cytokines such as TNF and interleukin-6. These cytokines amplify local inflammation, promote the osteogenic differentiation of resident progenitor cells, and stimulate the expression of matrix metalloproteinases, a family of proteolytic enzymes that degrade extracellular matrix components and drive maladaptive tissue remodeling.

To characterize the inflammatory and tissue-remodeling profile of the sclerotic phase, the team conducted a cross-sectional study of 168 participants at the Instituto Nacional de Cardiología Ignacio Chávez. The cohort comprised 29 clinically healthy volunteers with normal aortic valve morphology and function, 98 volunteers with aortic valve sclerosis, and 41 patients with established calcific aortic stenosis recruited from the outpatient cardiology clinic as candidates for elective valve replacement. Healthy volunteers were drawn from hospital staff and patient relatives and classified by transthoracic echocardiography performed by a single experienced cardiologist blinded to clinical and laboratory data. Sclerosis was defined as a peak aortic valve velocity below 2.0 meters per second with focal echogenicity and leaflet thickening without motion restriction, while stenosis was graded by aortic valve area and mean transvalvular gradient according to current American Society of Echocardiography and European Association of Cardiovascular Imaging recommendations. Exclusion criteria were rigorous, screening out coronary artery disease, renal or hepatic dysfunction, recent acute infections, autoimmune disease, bicuspid aortic valves, and rheumatic valve disease, all of which could confound the circulating biomarker measurements.

After an overnight fast, peripheral venous blood was collected from each participant, and serum concentrations of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TNF, interleukin-6, and transforming growth factor-beta were quantified using commercially available enzyme-linked immunosorbent assay kits, with all measurements performed in duplicate and coefficients of variation below 10 percent. Statistical analysis was deliberately conservative. Because most variables were non-normally distributed, the team used nonparametric tests, adjusted all pairwise comparisons with the Benjamini-Hochberg false discovery rate procedure, and then constructed multivariable linear regression models in which biomarkers were analyzed as dependent variables after logarithmic transformation. Disease stage was included as the main independent variable using dummy coding with the normal valve group as reference, and models were adjusted for age, sex, body mass index, systolic blood pressure, fasting glucose, and LDL-cholesterol, ensuring that the associations reported were independent of major clinical and metabolic confounders.

The results paint a striking picture of the sclerotic phase. Patients with aortic valve sclerosis had significantly higher circulating MMP-9 concentrations than both the stenosis group, with median levels of 2,375 picograms per milliliter compared with 2,090, and the normal valve group, where levels averaged 1,948. MMP-2 was also higher in sclerosis than in stenosis, though it did not differ significantly from normal valves. TIMP-1, the tissue inhibitor of metalloproteinases-1, moved in the opposite direction, falling to a median of 233 picograms per milliliter in sclerosis compared with 354 in stenosis and 436 in normal valves. Among the cytokines, TNF levels were higher in sclerosis than in stenosis, at 403 versus 328 picograms per milliliter, while interleukin-6 and transforming growth factor-beta did not differ among groups. No significant differences were observed for MMP-1 or MMP-3. After adjustment for multiple comparisons, the key findings retained high statistical significance, with q values near 0.001 for MMP-9, TIMP-1, and the proteolytic ratios, and the TNF difference remained significant at a marginal q value of 0.040.

The most notable result, however, was the proteolytic balance itself. The MMP-9/TIMP-1 ratio, a measure of net matrix-degrading activity, was markedly increased in aortic valve sclerosis, reaching a median of 11.0 compared with 4.4 in stenosis and 4.8 in normal valves. The MMP-2/TIMP-1 ratio was similarly elevated in sclerosis relative to stenosis, and the MMP-3/TIMP-1 ratio was higher in sclerosis than in normal valves. Critically, these findings persisted in the multivariable models. Using the normal valve group as reference, aortic valve sclerosis remained independently associated with a higher MMP-9/TIMP-1 ratio, with a regression coefficient of 0.78 and a 95 percent confidence interval of 0.52 to 1.04, higher MMP-9 levels, and lower TIMP-1 concentrations. In contrast, MMP-2 levels and the MMP-2/TIMP-1 ratio were not independently associated with sclerosis after adjustment, and established stenosis exhibited a different biomarker profile with no significant increase in the MMP-9/TIMP-1 ratio when compared with normal valves.

At the molecular level, the authors interpret these findings as evidence of a selective inflammatory activation in the sclerotic phase. TNF, as an upstream regulator of valvular inflammation, is capable of activating endothelial cells, inducing adhesion molecule expression, and promoting LDL uptake, effects that collectively facilitate immune cell recruitment and early lesion development. By analogy with atherosclerosis, enhanced TNF signaling in the valvular endothelium may promote leukocyte infiltration and early matrix remodeling, reinforcing the view that sclerosis represents an immune-mediated and metabolically driven stage of valve disease rather than a passive, age-dependent degenerative process. Beyond inflammation, the data reveal a profound shift in the proteolytic balance. Elevated MMP-9, which degrades fibrillar collagens and elastin, combined with reduced TIMP-1, produces an enzymatic milieu that favors extracellular matrix degradation and may accelerate the transition from a thickened, non-calcified valve to a calcified, stenotic lesion. Similar increases in circulating MMP-9 and the MMP-9/TIMP-1 ratio have been associated with atherosclerotic plaque instability and adverse cardiovascular events, underscoring the mechanistic parallel between the two diseases.

From a clinical perspective, the implications are considerable. The coexistence of systemic inflammation and proteolytic activation in the sclerotic phase suggests that early therapeutic modulation may delay or prevent progression toward stenosis. Statins, for instance, possess anti-inflammatory and anti-MMP properties beyond lipid lowering, and although large clinical trials in established stenosis have been largely negative, their efficacy in earlier disease stages deserves renewed investigation. Experimental strategies targeting MMP activity, such as doxycycline, or inflammatory cytokines, such as TNF antagonists, could theoretically stabilize the valvular matrix, though these approaches remain largely untested in valvular disease. Anti-TNF therapy has been shown to reduce aortic inflammation and stiffness in patients with rheumatoid arthritis, providing a proof of concept that cytokine modulation can alter vascular biology. Recognizing aortic valve sclerosis as an inflammatory phenotype rather than an incidental echocardiographic finding also emphasizes its role as a marker of systemic atherosclerotic burden, given prior evidence linking sclerosis to increased risk of coronary artery disease and acute coronary syndromes.

The study has limitations that temper causal interpretation. Its cross-sectional design precludes inference about progression from sclerosis to stenosis, and the stenosis patients were significantly older and had more comorbidities, including a high prevalence of obesity, hypertension, and diabetes, reflecting real-world demographics but complicating direct comparisons. The team quantified circulating biomarkers, which may not fully represent local valvular processes, and future studies integrating serum and tissue analyses could clarify whether systemic alterations mirror local molecular events. Longitudinal studies are warranted to determine whether the biomarker profile identified here predicts progression to clinically significant stenosis. Nevertheless, the evidence that the combination of elevated TNF, increased MMP-9, and reduced TIMP-1 defines a biological signature of valvular inflammation and matrix remodeling, already established before overt hemodynamic obstruction occurs, opens new avenues for preventive and targeted strategies aimed at halting disease progression before irreversible calcification develops. What was once dismissed as benign wear and tear is emerging as an active, modifiable disease process, and the window for intervention may be far earlier than previously imagined.

Subject of Research: A cross-sectional study of 168 participants reports that aortic valve sclerosis is characterized by elevated circulating MMP-9, reduced TIMP-1, a markedly increased MMP-9/TIMP-1 ratio, and higher TNF levels compared with aortic stenosis, suggesting an active inflammatory and proteolytic phase of calcific aortic valve disease that may be amenable to early targeted intervention.

Article Title: Matrix metalloproteinase activation and TNF upregulation characterize the sclerotic phase of aortic valve disease

Article References: Chan-Delgado, E., Lerma, C., Echeverría, J. C., Toledo, A., Torres-Arellano, J. M., Infante, O., Bojalil, R., Cossío-Aranda, J. E., Ávila-Vanzzini, N., Amezcua-Guerra, L. M., & Springall, R. (2026). Matrix metalloproteinase activation and TNF upregulation characterize the sclerotic phase of aortic valve disease. British Journal of Biomedical Science, 83, Article 16540. https://doi.org/10.3389/bjbs.2026.16540

Image Credits: AI Generated

DOI: 10.3389/bjbs.2026.16540

Keywords: aortic valve sclerosis, aortic stenosis, matrix metalloproteinases, TNF, extracellular matrix, cardiovascular disease, inflammation, calcific aortic valve disease, Matrix, metalloproteinase, activation, upregulation

The condition in question is coronary microvascular dysfunction, or CMD, a disorder of the tiny arteries and arterioles that branch off the main coronary arteries. While major coronary blockages are easy to spot on an angiogram, the microvasculature operates at a scale beyond direct imaging. When these small vessels fail to dilate properly, the heart muscle cannot increase its blood supply during stress, even when the large arteries look clean. In aortic stenosis, the thickened heart muscle wall demands more oxygen while the high pressure inside the heart chamber compresses the microcirculation, creating a perfect storm for microvascular impairment.

A team of researchers from Thailand, led by Maethas Panyawongkhanti and colleagues, systematically searched five databases for studies published between January 2010 and December 2025 that assessed CMD in adults with severe aortic stenosis undergoing TAVI. The team accepted only rigorous measurement techniques: wire-based thermodilution, which threads a pressure-temperature sensor into the coronary artery; angiography-derived indices calculated from routine catheterization images; Doppler ultrasound measurements of coronary flow; and stress cardiac magnetic resonance imaging. The protocol was prospectively registered and the analysis followed PRISMA 2020 reporting standards, with study quality graded using the Newcastle-Ottawa Scale and the certainty of evidence evaluated under the GRADE framework.

Eleven primary studies made the final cut. Ten of them, encompassing 1,212 patients, contributed to the prevalence analyses, while an additional study of 126 patients entered only the sensitivity analyses. The headline finding was striking: the pooled prevalence of CMD before TAVI was 46.8 percent. But that number came with a caveat that turned out to be the study’s most important message. When CMD was measured with wire-based thermodilution, the gold standard involving direct intracoronary sensors, prevalence was 46.8 percent across six studies and 324 patients. When angiography-derived indices were used instead, across four studies and 888 patients, prevalence dropped to 38.4 percent, with essentially no statistical heterogeneity between those studies.

The discrepancy between modalities is not merely academic. Wire-based thermodilution measures the minimal microvascular resistance directly, an absolute physiological quantity expressed in units of pressure times time divided by flow. Angiographic indices, by contrast, are relative ratios that compare resting and hyperemic states and can be influenced by factors such as resting flow velocity, heart rate, and the pressure gradient across the stenotic valve itself. Because the two approaches define CMD differently, they cannot be assumed to identify the same patients. The high heterogeneity statistic of 72 percent in the thermodilution group reflected non-equivalent CMD definitions across studies, meaning that the pooled figure should be interpreted as a range rather than a precise point estimate.

The researchers also tracked what happens to the microcirculation after the valve is replaced. Coronary flow reserve, or CFR, the ratio of hyperemic to resting coronary blood flow, increased after TAVI by a pooled mean difference of 0.49, with a 95 percent confidence interval of 0.27 to 0.71, across five studies and 103 paired observations. On the surface, this looks like good news: the microvasculature appears to recover once the valve obstruction is gone. But the authors caution that the improvement may be deceptive. CFR is a ratio, and when resting blood flow demand falls after valve replacement, the denominator of the ratio shrinks, mechanically inflating the reserve even if the absolute capacity of the microcirculation is unchanged.

The narrative synthesis of microvascular resistance data supported exactly that interpretation. Reductions in microvascular resistance were confined to pressure-to-velocity and reserve ratio indices, which are relative measures sensitive to changes in resting conditions. In contrast, absolute minimal microvascular resistance, the most direct measure of the microcirculation’s structural capacity, showed no significant change after TAVI across four studies and 85 patients. In other words, the heart’s resting oxygen demand drops after valve replacement, which makes the reserve ratios look better, but the underlying architecture of the microvasculature may remain impaired. This distinction matters because structural microvascular damage, such as fibrosis and capillary rarefaction in the chronically hypertrophied heart muscle, is unlikely to reverse simply by removing the valve obstruction.

The prognostic question, whether CMD before TAVI predicts major adverse cardiovascular events, or MACE, after the procedure, yielded a hypothesis-generating rather than definitive answer. Across two studies and 585 patients, the hazard ratio for MACE associated with baseline CMD was 3.22, with a 95 percent confidence interval of 0.98 to 10.60 and substantial heterogeneity of 78 percent. The confidence interval crosses unity, meaning the association is not statistically significant at the conventional threshold, and the wide range reflects the small number of contributing studies and the incompatible hazard ratio calculations used in the original research. The authors explicitly state that the CMD-MACE association should be viewed as hypothesis-generating due to limited studies, varied CMD definitions, and incompatible statistical approaches.

What emerges from this review is a nuanced picture of a common but underrecognized complication. Coronary microvascular dysfunction affects a substantial proportion, plausibly between one-third and one-half, of patients with severe aortic stenosis before valve replacement, and the diagnostic method fundamentally shapes the estimated burden. TAVI improves coronary flow reserve, but likely by reducing resting demand rather than by repairing the microcirculation itself. Whether CMD independently predicts poor outcomes after TAVI remains an open question that the current evidence cannot settle.

The authors call for prospective multicenter studies with standardized CMD definitions to resolve these uncertainties. Such studies would need to agree on diagnostic thresholds, follow patients over meaningful time horizons, and use compatible statistical methods for prognostic modeling. Until then, the message for clinicians is clear: a successful valve replacement does not guarantee a fully healthy microcirculation, and the tools used to assess it are not interchangeable. For the growing population of elderly patients undergoing TAVI worldwide, the microscopic vessels of the heart may represent the next frontier in structural heart disease care.

Subject of Research: Coronary microvascular dysfunction prevalence, post-TAVI coronary flow reserve changes, and prognostic significance in severe aortic stenosis patients undergoing transcatheter aortic valve implantation

Article Title: Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation: A systematic review and meta-analysis

Article References: Panyawongkhanti, M., Chintrakulchai, P., Tanking, C., & Luangphiphat, W. (2026). Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation: A systematic review and meta-analysis. PLOS One, 21(10), e0360374. https://doi.org/10.1371/journal.pone.0360374

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360374

Keywords: coronary microvascular dysfunction, TAVI, aortic stenosis, coronary flow reserve, meta-analysis, PLOS One, cardiology, heart disease, Coronary, microvascular, dysfunction, patients

The study, published in Clinical Research in Cardiology, analyzed 2,002 patients who underwent transfemoral TAVI between April 2011 and January 2023. All patients had high-quality computed tomography angiography scans of their peripheral vessels, allowing the investigators to reconstruct the three-dimensional path of the iliac and femoral arteries with dedicated software. The median age of the cohort was 81 years, 45.2 percent were women, and the median EuroScore II, a measure of surgical risk, was 4.22, reflecting the typically frail population that receives these valves.

The tortuosity index itself is elegantly simple. Using centerline reconstruction of the CT scan, the team measured the true length of the vessel path from the aorto-iliac bifurcation down to the epigastric artery, then divided that by the straight-line distance between the same two points. A perfectly straight vessel would score 1.0. Borrowing from guidelines developed for endovascular aortic aneurysm repair, the researchers classified vessels into four grades and dichotomized patients into a low tortuosity group with an index at or below 1.5 and a high tortuosity group above 1.5.

The results were striking. At six months of follow-up, 7.9 percent of patients in the high tortuosity group had died, compared with 5.2 percent of those in the low tortuosity group, a difference that reached statistical significance. After adjusting for peripheral artery disease, creatinine clearance, and prior myocardial infarction using Cox proportional hazard modeling, a tortuosity index above 1.5 remained independently associated with mortality, carrying a hazard ratio of 1.679. When the index was treated as a continuous variable, each unit increase was associated with an even larger hazard ratio of 3.593.

Perhaps the most intriguing aspect of the finding is that the high tortuosity group was not simply sicker in the conventional sense. Although these patients were older, they actually had a lower prevalence of established mortality-related comorbidities, including diabetes, arterial hypertension, coronary artery disease, and malignancy. This suggests that the excess mortality cannot be explained by a heavier burden of traditional risk factors, and that the winding shape of the arteries may itself carry prognostic information.

The authors propose that vascular tortuosity may act as a marker of frailty and biological aging. Arteries elongate and kink as elastic fibers degrade over decades, and previous work has linked tortuosity in non-atherosclerotic vascular disease to age, aneurysms, and hypertension. In this framing, a highly tortuous iliac artery is less a direct cause of death than a visible fingerprint of a vascular system, and a patient, that has aged faster than the calendar suggests. The researchers caution that they could not calculate formal frailty indices in this retrospective cohort, so this hypothesis remains to be confirmed in prospective studies.

Notably, the tortuosity index did not predict periprocedural vascular complications in this cohort. Major vascular complications occurred in 16 percent of all patients and minor complications in 18.6 percent, with no significant difference between the low and high tortuosity groups. Puncture-related bleeding was the most frequent cause of access-site problems, followed by dissection or stenosis and pseudoaneurysm. The authors attribute this apparent disconnect to the dramatic technological evolution of TAVI over the study period, including lower-profile delivery systems, flexible introducer sheaths, ultrasound-guided puncture, and improved closure techniques, which have driven vascular complication rates down from roughly 15 percent in the earliest era to as low as 0.7 to 1.5 percent in contemporary practice.

The temporal dimension of the data adds nuance. Within the registry, 26 percent of major vascular complications occurred in patients treated before 2018, versus only 9.6 percent after that year. The statistical interaction between the tortuosity-mortality association and the year of treatment was significant, yet the index remained predictive of death even after adjustment for treatment year and period. This suggests that while better devices and growing operator experience have blunted the mechanical hazards of navigating twisted vessels, the prognostic signal embedded in arterial geometry persists, hinting at a biology that technology cannot yet override.

For clinicians, the practical message is that the tortuosity index, already validated for planning large-bore access in endovascular aneurysm repair, can be applied to TAVI patients using the same CT scans they already receive. A value above 1.5 may flag a higher-risk population deserving extra scrutiny during preprocedural planning, from ultrasound-guided access and high-support guidewires to straightening maneuvers and careful choice of access side. The study has limitations, including its single-center retrospective design, six-month follow-up, and the exclusion of roughly 40 percent of screened patients who lacked suitable CT imaging. Still, the idea that a number as mundane as a length ratio, calculated in seconds from an existing scan, could whisper something profound about a patient’s resilience is a compelling reminder that in medicine, sometimes the shape of things says as much as their substance.

Subject of Research: Association between peripheral vessel tortuosity index and six-month mortality after transfemoral transcatheter aortic valve implantation

Article Title: Peripheral vessel tortuosity index and prognosis in patients undergoing transcatheter aortic valve implantation

Article References: Alvarez-Covarrubias, H. A., Jurisic, M., Seguchi, M., Salzmann, C., Hug, K., Hübner, J., Starnecker, F., Syryca, F., Haug, F., Pellegrini, C., Rheude, T., Mayr, N. P., Cassese, S., Kastrati, A., Xhepa, E., & Joner, M. (2026). Peripheral vessel tortuosity index and prognosis in patients undergoing transcatheter aortic valve implantation. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03035-w

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03035-w

Keywords: transcatheter aortic valve implantation, TAVI, tortuosity index, peripheral artery disease, computed tomography angiography, vascular complications, mortality, frailty, transfemoral access, iliac artery, aortic stenosis, cardiology

The research team, led by investigators including Ramin Ebrahimi, Paul A. Dennis, and Jennifer A. Sumner, drew on national electronic health records spanning 2000 to 2019, a period covering multiple military service eras. Women veterans represent the fastest-growing group within the Veterans Health Administration, nearly tripling in number from roughly 160,000 in 2000 to nearly 440,000 in 2015, and they are projected to account for nearly 18 percent of all living US veterans by 2040. Yet despite carrying a heavier burden of both psychiatric and traditional cardiovascular risk factors than civilian women or male veterans—and experiencing higher cardiovascular mortality—they have been strikingly underrepresented in research on the PTSD-heart disease connection.

Methodologically, the study was designed to guard against the confounding that has plagued earlier work in this field. The investigators identified 622,312 women veterans with at least one VHA healthcare encounter, then excluded anyone with pre-existing cardiovascular disease. From this pool, 140,210 women with documented PTSD were matched to 101,448 women without the disorder using propensity score methods. Rather than relying on conventional statistical matching, the team employed extreme gradient boosting, a machine learning algorithm that iteratively models residuals to capture complex interactions among dozens of variables, including demographics, traditional risk factors such as hypertension and smoking, female-specific risks like preeclampsia, and a range of mental health conditions from depression to substance use disorders.

The matching process achieved excellent balance across all measured covariates, with standardized mean differences falling below the conventional threshold of 0.10. The resulting cohort had a mean age of 39.1 years, with fewer than 5 percent aged 60 or older, and was notably diverse: just over half were non-Hispanic White, roughly 30 percent non-Hispanic Black, and more than 9 percent Hispanic/Latina. Cardiovascular outcomes were identified using strict diagnostic code criteria—requiring at least one inpatient or two outpatient records for each condition—an approach validated in prior Department of Veterans Affairs research with reported sensitivity and specificity above 0.95 for PTSD identification.

Over an average follow-up of roughly six years, 7.5 percent of women with PTSD developed at least one of the cardiovascular conditions in the composite outcome, compared with 5.5 percent of women without PTSD—a 36 percent relative increase in crude cumulative incidence. In survival models accounting for the competing risk of death, PTSD was associated with a 24 percent higher rate of incident cardiovascular disease overall. The association held for ischemic heart disease, with a hazard ratio of 1.30, and for stroke and transient ischemic attack, with a hazard ratio of 1.29, consistent with meta-analytic estimates from earlier studies that had reported pooled hazard ratios of approximately 1.6 for coronary heart disease and stroke.

What distinguishes this study is its reach beyond the familiar territory of heart attacks and strokes. The researchers found significant associations between PTSD and heart failure, venous thromboembolism, pulmonary hypertension, and aortic valve stenosis. The link with venous thromboembolism was among the strongest observed, with a hazard ratio of 1.34, while aortic stenosis showed a hazard ratio of 1.23 and pulmonary hypertension 1.17. Associations with atrial fibrillation and peripheral arterial disease were elevated but did not reach statistical significance, possibly because these conditions remain rare in a cohort of women in their late thirties followed for only about six years.

Perhaps the most striking findings emerged from stratified analyses. The PTSD-cardiovascular connection was strongest in the youngest women: those aged 30 to 39 showed a hazard ratio of 1.52, and those aged 18 to 29 a hazard ratio of 1.42, compared with more modest elevations in older age groups. Racial and ethnic disparities were equally pronounced. American Indian/Alaska Native women with PTSD had a 58 percent higher rate of cardiovascular disease, and Hispanic/Latina women a 50 percent higher rate, compared with their counterparts without PTSD. The authors caution that small sample sizes for some subgroups produced wide confidence intervals, but the pattern suggests that certain populations may bear a disproportionate share of PTSD-related cardiovascular risk.

The biological plausibility of these associations rests on well-characterized pathways. PTSD has been linked to unhealthy behaviors including physical inactivity, poor diet, disrupted sleep, and smoking, as well as to comorbid depression and substance use disorders that independently elevate cardiovascular risk. Beyond behavior, the disorder involves dysregulation of the hypothalamic-pituitary-adrenal axis and hyperreactivity of the sympathetic nervous system, particularly in response to trauma-related reminders. These stress-system disturbances can drive vasoconstriction, endothelial dysfunction, arterial stiffness, and increased cardiac afterload—mechanisms that plausibly contribute to ischemic heart disease and stroke. Immune dysregulation and chronic systemic inflammation, also documented in PTSD, may underlie connections to heart failure and pulmonary hypertension specifically.

Notably, prior work by the same research group found that traditional and nontraditional risk factors together explained less than half of the association between PTSD and incident ischemic heart disease in women veterans, implying that much of the excess risk operates through pathways not yet captured in electronic health records. The authors call for mechanism-focused research into modifiable factors such as sleep patterns, physical activity, and trauma-related processes, which could open new avenues for prevention tailored to this high-risk population.

The clinical implications are difficult to ignore. Current cardiology guidelines have historically categorized women under 45 as low-risk for cardiovascular events, and the most recent VA/Department of Defense dyslipidemia guidelines recommend screening only from age 40, with no mention of PTSD status. Yet this study found the strongest PTSD-related risk precisely in women under 40, and earlier research showed that ten-year cardiovascular risk rises steadily from age 30 in women veterans. The findings argue for earlier and more tailored cardiovascular risk assessment in women veterans with PTSD, and the Veterans Health Administration has begun developing a Cardiovascular Toolkit aimed at improving risk identification and patient education for women veterans. The researchers also emphasize the need to determine whether similar early risk elevation exists in non-veteran women and men with PTSD, to verify the novel associations with aortic stenosis and pulmonary hypertension, and to test whether targeted interventions can blunt the cardiovascular toll of trauma-related illness.

Subject of Research: The association between posttraumatic stress disorder and incident cardiovascular disease in women veterans

Article Title: Impact of posttraumatic stress disorder on incident cardiovascular outcomes in women veterans: a retrospective longitudinal study

Article References: Ebrahimi, R., Dennis, P. A., Alvarez, C. A., Shroyer, A. L., Beckham, J. C., & Sumner, J. A. (2026). Impact of posttraumatic stress disorder on incident cardiovascular outcomes in women veterans: a retrospective longitudinal study. eClinicalMedicine, 100, Article 104197. https://doi.org/10.1016/j.eclinm.2026.104197

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104197

Keywords: PTSD, cardiovascular disease, women veterans, heart failure, venous thromboembolism, aortic stenosis, pulmonary hypertension, stroke, ischemic heart disease, propensity score matching, Veterans Health Administration, health disparities

The study, led by Ottavia Cozzi and Daijiro Tomii of Bern University Hospital together with senior author Thomas Pilgrim, categorized 732 patients according to computed tomography-derived annular area, defining a small annulus as 430 square millimeters or less. This threshold is the most widely applied cut-off in the contemporary literature, and the researchers also ran sensitivity analyses using stricter definitions of 386 and 400 square millimeters. The results held firm across all definitions. In total, 323 patients, or 44.1 percent of the cohort, had a small annulus, underscoring just how frequently this anatomy appears in clinical practice.

The demographic profile of these patients was striking. More than 84 percent of those with a small annulus were women, compared with just over a third of patients with larger annuli. Women with severe aortic stenosis often present with more advanced disease and greater frailty at the time of intervention, a pattern thought to reflect later detection and delayed referral. Patients with small annuli also carried slightly higher predicted surgical risk, with a median Society of Thoracic Surgeons Predicted Risk of Mortality score of 3.8 percent versus 3.3 percent. By contrast, atrial fibrillation, obstructive coronary artery disease, and prior cardiothoracic surgery were more common among those with larger annuli, painting two distinct clinical phenotypes.

Hemodynamically, the small-annulus group did face measurable disadvantages. Thirty days after the procedure, echocardiography revealed higher mean transprosthetic gradients of 10 millimeters of mercury compared with 8 in the larger-annulus group, and a higher prevalence of residual gradients exceeding 20 millimeters of mercury. The effective orifice area and its indexed value were both significantly smaller, translating into a higher rate of moderate or severe prosthesis-patient mismatch, a condition in which the implanted valve is too small relative to the patient’s body size to permit unimpeded blood flow. In theory, such suboptimal forward flow should reduce exercise capacity and erode quality of life.

Yet the clinical data told a different story. At three years, all-cause mortality was actually numerically lower in the small-annulus group, at 18.6 percent versus 25.4 percent, a difference that was not statistically significant after adjustment. Cardiovascular death and hospitalization for heart failure were likewise comparable between groups. The researchers went a step further by evaluating an integrated patient-centered endpoint: being alive with good health status, defined as a Kansas City Cardiomyopathy Questionnaire overall summary score of at least 75 without a decline of more than 10 points from baseline. At three years, 46.5 percent of small-annulus patients achieved this demanding benchmark, compared with 43.2 percent of those with larger annuli, an odds ratio of 0.95 that was firmly within the range of chance.

Patient-reported health status itself followed a similar trajectory in both groups. Baseline Kansas City Cardiomyopathy Questionnaire scores were nearly identical, hovering in the mid-50s, and rose sharply after valve replacement in both cohorts. Although patients with small annuli experienced a slightly smaller early improvement at 30 days, ordinal analysis showed that more than 70 percent of patients in both groups enjoyed at least mild improvement at one and three years. By the three-year mark, median overall summary scores remained in the low 80s for both groups, indicating sustained, meaningful recovery in symptoms, physical limitation, and quality of life after the procedure.

The most provocative finding emerged from an exploratory factorial analysis examining the interplay between annular size and valve type. The SCOPE I trial had randomized patients to either the self-expanding ACURATE Neo from Boston Scientific or the balloon-expandable SAPIEN 3 from Edwards Lifesciences. When the investigators crossed annular size with valve type, a statistically significant interaction appeared for the patient-centered outcome. Patients with a small annulus treated with the balloon-expandable SAPIEN 3 had a lower probability of being alive with good health status at three years, with a relative risk of 0.59 and a p-value for interaction of 0.004. No such difference between valve types was seen in patients with larger annuli.

The mechanism behind this interaction remains speculative. The authors note that the intra-annular leaflet position of the balloon-expandable platform, together with differences in skirt design, frame expansion within a constrained annulus, and commissural alignment, may yield less favorable forward hemodynamics than a supra-annular design. They also point to the randomized SMART trial, which compared the SAPIEN 3 with the supra-annular Evolut valve specifically in small-annulus patients and found better echocardiographic valve performance and more frequent health-status improvement with the self-expanding device, though without differences in hard clinical endpoints. The researchers caution that echocardiography may systematically favor supra-annular devices due to measurement methodology, and that the apparent hemodynamic superiority should not be equated with definitive clinical advantage.

Several caveats temper the conclusions. As a post-hoc analysis, the study was not powered to detect differences by annular size, and all interaction analyses are exploratory. Residual imbalances persisted in sex, left ventricular ejection fraction, and serum creatinine even after propensity-based overlap weighting. Questionnaire data were available only for survivors who completed follow-up, and objective exercise testing was not systematically collected, leaving open the possibility of subtle functional differences. The advanced age of the cohort, with a median of 83 years, may also have blunted the functional impact of suboptimal hemodynamics, and the findings may not extend to younger, more active patients treated at lower surgical risk.

Practical implications nonetheless emerge. A small aortic annulus, present in more than 40 percent of TAVR candidates and overwhelmingly among women, should not be regarded as a barrier to excellent outcomes. The hemodynamic penalties visible on echocardiography do not translate into worse survival or diminished quality-of-life recovery over three years in well-selected patients. At the same time, the valve-type interaction hints that device selection may matter more in this anatomy than previously appreciated, a hypothesis that will require confirmation in adequately powered studies with contemporary devices, particularly as the ACURATE platform has since been withdrawn from clinical use and newer iterations of balloon-expandable valves have shown improved hemodynamics in smaller sizes. For now, the message to patients and physicians alike is one of cautious reassurance.

Subject of Research: Impact of small aortic annulus size on clinical and quality-of-life outcomes after transcatheter aortic valve replacement

Article Title: Relationship between a small aortic annulus and clinical and quality-of-life outcomes in patients undergoing TAVR

Article References: Cozzi, O., Tomii, D., Lanz, J., Heg, D., Thiele, H., Kim, W.-K., Joner, M., Thilo, C., Toggweiler, S., Prendergast, B., Windecker, S., Pilgrim, T., & the SCOPE I Investigators (2026). Relationship between a small aortic annulus and clinical and quality-of-life outcomes in patients undergoing TAVR. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03025-y

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03025-y

Keywords: TAVR, aortic stenosis, small aortic annulus, prosthesis-patient mismatch, Kansas City Cardiomyopathy Questionnaire, transcatheter heart valve, SCOPE I trial, patient-reported outcomes, valve hemodynamics, cardiology, heart valve replacement, clinical outcomes

In-silico trials have already proven their utility across a remarkable range of cardiovascular applications, from planning Fontan surgeries for congenital heart defects to optimizing drug delivery, stent placement, and transcatheter aortic valve implantation, widely known as TAVI. Yet the field suffers from persistent methodological weaknesses. Clinical datasets used to seed these simulations are often small, demographics are inconsistently represented, uncertainty is poorly quantified, and data transparency remains limited. A virtual trial is only as trustworthy as the population it simulates, and building a convincing virtual population requires access to hundreds or thousands of detailed anatomical models that real hospitals simply cannot provide at scale. Synthetic data generation has emerged as the most practical remedy, and machine learning methods have proven the most effective among the available techniques.

Until now, the dominant tool for statistical shape analysis in this domain has been the statistical shape model, or SSM, typically built on principal component analysis. These classical models rest on two restrictive assumptions: that shape variation is essentially linear, and that every shape can be described through point-to-point correspondence with every other shape in the dataset. Both assumptions break down when confronted with the complex, nonlinear deformations of real cardiovascular anatomy, and establishing point correspondence across patient meshes is labor-intensive and error-prone. Nonlinear extensions using kernel methods and manifold learning have partially relaxed these constraints, but they introduce heavy computational overhead and generalize poorly.

The Romanian team’s framework sidesteps these limitations entirely by adopting implicit neural representations, a family of techniques that encode three-dimensional shapes as continuous mathematical functions rather than discrete collections of points or voxels. At the heart of the approach lies a signed distance field, or SDF, a function that assigns to every point in space its distance to the object’s surface, with the sign indicating whether the point lies inside or outside. The surface itself is implicitly defined as the zero-level set of this field. Because a neural SDF is continuous and resolution-independent, it avoids the discretization biases of voxel grids, the memory overhead of volumetric representations, and the topological information loss that plagues point-cloud decoders. Unlike classical mesh-based models, it is also topology-agnostic, meaning the same architecture can represent wildly different anatomical structures.

A key technical innovation concerns how the network is trained. The seminal DeepSDF method of Park and colleagues required ground truth signed distance values, which are only well-defined for watertight surfaces with unambiguous interiors. Real aortic geometries, being open tubular structures reconstructed from cardiac CT scans, are anything but watertight. The researchers instead employed implicit geometric regularization, an approach introduced by Gropp and colleagues that exploits the fact that a true signed distance function satisfies the Eikonal partial differential equation, meaning the gradient of the field has unit magnitude everywhere. By penalizing deviations from this condition at randomly sampled points in space, and by combining it with zero-level constraints on surface points and alignment with surface normal vectors, the network learns a faithful distance field from surface samples alone, with no ground truth distance values required.

Handling non-watertight geometry demanded one further component. When the network’s zero-level set is extracted from an open surface, it produces a closed shape that includes extraneous regions beyond the anatomy of interest. To solve this, the team trained an auxiliary boundary classifier that labels each point as belonging to the inlet, the outlet, or the remaining surface. Fitted planes through the classified inlet and outlet points allow the reconstructed mesh to be precisely truncated, isolating the aortic root. The complete pipeline operates as an autodecoder: each training shape receives a trainable latent vector of 128 dimensions, and a network of roughly 1.7 million parameters, organized in eight fully connected layers with softplus activations and a skip connection, maps these latent codes and spatial coordinates to distance values. At inference, new shapes are decoded through the Marching Cubes algorithm on a 256-cubed grid, then truncated and rescaled to physical dimensions.

The framework was trained on 73 peak-systole aortic surface meshes reconstructed from cardiac CT images of patients scheduled for TAVI procedures, each clinically validated by expert cardiologists. Calcifications were represented as separate meshes, and a second, conditioned implicit network was trained to generate calcium deposits attached to a given aortic shape by receiving the aortic latent vector as an additional input. Reconstruction fidelity was measured with symmetric Chamfer distance, achieving a mean of just 0.135 square millimeters for aortic roots, evidence of high-fidelity geometric representation. New synthetic patients were produced by linearly interpolating between pairs of learned latent vectors, and from this process the team generated a validation cohort of 2,500 synthetic patients stratified by gender.

The critical question is whether these synthetic hearts pass clinical muster, and the answer appears to be yes. The researchers extracted diagnostically relevant features from both real and synthetic cohorts by slicing each mesh at half-millimeter intervals along the blood flow direction, identifying four anatomically significant cross-sections: the aortic annulus, the left ventricular outflow tract, the sino-tubular junction, and the aortic sinus. They also computed aortic valve area using a custom iterative ray-casting algorithm that converged in roughly five iterations and matched ground truth CT measurements with a mean absolute error of 0.092 square centimeters. Synthetic annulus diameters averaged 24.31 plus or minus 1.65 millimeters, closely matching the 24.6 plus or minus 2.4 millimeters reported in clinical literature for aortic stenosis populations. Statistical tests, including the Mann-Whitney U test and Welch’s t-test, found no significant differences in distribution or mean for any feature, and the distribution of aortic stenosis severity, classified as mild, moderate, or severe according to valve area thresholds, aligned well between real and synthetic cohorts.

The calcification results are perhaps the most striking. Generated calcium deposits localized to regions of mechanical stress and geometric irregularity within the conditioned aortic shape, exactly where aortic stenosis pathology develops in real patients. The deposits exhibited realistic size, morphology, and density variations that correlated with stenosis severity, and histogram analysis of 500 synthetic calcifications per shape showed spatial distributions closely matching real ground truth patterns. One acknowledged trade-off is a modest reduction in variance across most anatomical measurements, an expected consequence of latent vector interpolation when generating far more shapes than the original dataset contained. The aortic valve area, notably, preserved its variability, suggesting the primary clinical indicator remains statistically intact. The authors anticipate that clinicians will eventually generate shapes from curated samples representing specific pathological conditions rather than through random interpolation, which should further attenuate the smoothing effect.

The implications extend well beyond the aortic root. The modular architecture generalizes to other cardiovascular structures, including watertight geometries such as heart chambers, where boundary classification becomes unnecessary. The learned latent vectors can serve as compact low-dimensional representations of patient anatomy, conditioning physics-informed surrogate models that predict hemodynamic quantities like transvalvular pressure gradients, paravalvular leakage flow, and wall shear stress across entire synthetic cohorts without running full-scale fluid simulations for each geometry. This could accelerate TAVI in-silico trials, where device performance is acutely sensitive to annulus diameter, sino-tubular junction dimensions, and calcification distribution. Funded by the European Union’s Horizon 2020 program under the SIMCor project, the work points toward a future where virtual patient populations, assembled on demand and tailored to specific study designs, become a standard pillar of cardiovascular device development, reducing the cost, duration, and ethical burden of bringing life-saving technologies to patients.

Subject of Research: Generative deep learning modeling of cardiovascular geometries for in-silico clinical trials

Article Title: Generative modelling of cardiovascular geometries for in-silico trials

Article References: Gasparovici, A., & Serban, A. (2026). Generative modelling of cardiovascular geometries for in-silico trials. Neural Computing and Applications, 38(18), Article 745. https://doi.org/10.1007/s00521-026-12463-8

Image Credits: AI Generated

DOI: 10.1007/s00521-026-12463-8

Keywords: implicit neural representations, signed distance field, in-silico trials, cardiovascular modeling, aortic root, synthetic data generation, TAVI, aortic stenosis, statistical shape models, calcifications, deep learning, virtual patients

TAVI has transformed the treatment of aortic stenosis, the narrowing of the heart’s main outflow valve that affects millions of older adults worldwide. Instead of opening the chest, clinicians thread a collapsible biological valve through an artery and deploy it inside the native valve’s calcified frame. Yet the procedure is not always perfect. In a substantial fraction of patients, the new valve does not expand symmetrically against the hardened calcium of the aortic root, leaving gaps through which blood leaks backward, a complication called paravalvular leakage. Mild to moderate leakage affects between 7 and 40 percent of TAVI patients, and when moderate or severe it is strongly associated with increased late mortality. The standard remedy is balloon post-dilation, in which a non-compliant balloon is inflated inside the freshly implanted stent to push calcifications outward and force the valve frame into fuller contact with the vessel wall. It is performed in roughly 13 to 54 percent of cases depending on the registry.

Despite how common the maneuver is, computational models of TAVI have almost universally ignored it. A recent scoping review cited by the authors examined 40 studies that used numerical simulation to predict TAVI outcomes and found that not a single one modeled balloon post-dilation. Two prior efforts, by Li and colleagues and by Akodad and colleagues, attempted to simulate the ballooning step, but neither calibrated the balloon’s material properties through physical testing nor validated their predictions against real post-operative images. That gap matters because the decision to perform post-dilation is a delicate risk-benefit calculation: the maneuver can enlarge the valve area, lower pressure gradients, and reduce leakage, but it carries risks including annular rupture, valve migration, stroke, conduction disturbances, and damage to the delicate leaflets of the new valve.

To close that gap, the Milan-based team reconstructed a True Dilatation non-compliant balloon, a commercially available device from BD, using reverse engineering. They photographed a physical balloon at high resolution, measured its dimensions with a digital caliper, and processed the images in ImageJ to extract precise geometry, then built a computer-aided design model reproducing the device’s 85-millimeter total length, 45-millimeter working length, and 21-millimeter maximum diameter, later scaling it to the 22, 24, and 26 millimeter sizes actually used in patients. The balloon wall was represented as a shell just 0.3 millimeters thick, and the model was meshed with triangular shell elements averaging 0.8 millimeters, matching the refinement of the stent mesh to keep contact calculations stable.

Crucially, the team did not simply assume the balloon’s mechanical behavior; they measured it. Specimens cut from real balloons were stretched in a bioreactor equipped with a precision load cell, in both the longitudinal and circumferential directions, through six full loading-unloading cycles. The resulting stress-strain curves revealed a Young’s modulus of approximately 600 megapascals, with nearly identical values in both directions, indicating that the material behaves as an essentially isotropic elastic solid. To validate this finding, the researchers inflated an intact 21-millimeter balloon with water in a custom 3D-printed rig, raising the pressure in half-atmosphere steps up to four atmospheres while measuring the external diameter with a caliper. When they replicated this experiment in the virtual world using their 600-megapascal material model, the simulated pressure-diameter curve matched the experimental measurements with a coefficient of determination of 0.97, with the closest agreement near the nominal working pressure of three atmospheres.

With the balloon model calibrated and validated, the researchers integrated it into the final configurations of patient-specific TAVI simulations previously developed by the same group. Four patients who underwent TAVI at Humanitas Research Hospital between 2017 and 2024 were retrospectively included, all of whom had received self-expanding valves and post-dilation, and all of whom had post-operative CT scans available for comparison. In the simulations, the crimped balloon was placed inside the virtually implanted stent, inflated to its nominal pressure to push calcifications against the aortic wall and fully expand the Nitinol frame, then deflated to capture any elastic recoil. Two of the four patients also carried mechanical mitral valve prostheses, which the models explicitly represented as rigid bodies to capture potential device-device interference. All computations ran on an explicit finite element solver, LS-DYNA, using damping and selective mass scaling to keep energy ratios under five percent and maintain a constant time increment of one microsecond.

The validation against clinical imaging delivered striking results. Comparing the simulated final stent geometry with that segmented from post-operative CT scans, the average error in orifice area across three cross-sectional planes was just 1.55 percent, with a standard deviation of 1.26 percent, while the error in stent eccentricity at the level of the left ventricular outflow tract averaged 1.54. More telling was the comparison with simulations that omitted post-dilation: including the ballooning step reduced the orifice area error from 3.1 percent to 1.6 percent, a 53 percent improvement, and slashed the eccentricity error from 7.4 percent to 1.5 percent, an 80 percent improvement. Centerline analysis, which measures how closely the simulated stent axis follows the real one, found a mean deviation of only 0.386 millimeters across all patients.

The researchers also explored what the geometry changes mean physiologically. Using a simplified geometric surrogate for paravalvular leakage based on peri-prosthetic flow volume, they found that post-dilation reduced the leakage-prone space in three of the four patients, suggesting improved sealing between device and wall. The fourth patient, who started with a very low baseline flow volume, showed essentially no change, a reminder that the benefits of ballooning depend heavily on each patient’s unique anatomy. The authors explain that the key mechanism is not material damage but the redistribution of contact constraints: the balloon displaces calcified deposits, which alters the available space for stent expansion, so after deflation the Nitinol frame settles into a new equilibrium that would never be predicted by a deployment-only simulation. Because calcification patterns differ so dramatically between patients, the effects of post-dilation can be non-uniform and even counterintuitive, which is precisely why patient-specific modeling is needed.

The implications reach beyond academic curiosity. The authors argue that a validated virtual post-dilation capability could support pre-operative planning in which clinicians first examine the predicted post-deployment configuration of the valve, checking stent expansion, eccentricity, and apposition to the annulus, and then virtually test whether ballooning with different balloon sizes would deliver meaningful improvement at an acceptable safety margin. Such digital twins could help operators decide when corrective ballooning is likely to help, and when it merely adds risk. The study does carry limitations: only four patients were analyzed, partly because routine post-operative CT imaging is not standard practice, and the models do not simulate aortic wall rupture or calcification fracture, nor do they compute actual blood flow for leakage quantification. Still, the researchers see this work as a clear step toward credible, clinically deployable in silico tools. Notably, a review of the field found that only about 10 percent of TAVI simulation studies validated their results against post-implant CT scans at all. By calibrating every component against benchtop experiments and every prediction against real clinical outcomes, this study sets a new benchmark for what rigorous validation in computational cardiology should look like, and it brings the vision of personalized, simulation-guided structural heart intervention measurably closer to the operating room.

Subject of Research: Patient-specific computational modeling and validation of balloon post-dilation in transcatheter aortic valve implantation

Article Title: In Silico Modeling and Validation of Post-Dilation in TAVI Patients

Article References: Perri, L. M., Grossi, B., Fregona, V., Barati, S., Barbieri, L., Tumminello, G. D., Carugo, S., Bianchi, E., De Stefano, P., Berti, F., Cozzi, O., Condorelli, G., Stefanini, G., Dubini, G., Rodriguez-Matas, J. F., Migliavacca, F., & Luraghi, G. (2026). In Silico Modeling and Validation of Post-Dilation in TAVI Patients. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04325-0

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04325-0

Keywords: TAVI, balloon post-dilation, finite element analysis, patient-specific simulation, paravalvular leakage, aortic stenosis, Nitinol stent, computed tomography, in silico medicine, biomedical engineering, model validation, digital twins